Alireza Eghtedar, MD
Hematology & Oncology · Denver, CONPI 1811280431
Payments from drug & device makers
Across 387 payments — averaging $1524.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$159K
- Astellas Pharma Global Development$153K
- Sumitomo Pharma America, Inc.$102K
- Novartis$96K
- Jazz Pharmaceuticals Inc.$57K
- Bristol Myers Squibb$15K
- plus $9K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $158,808 |
| Astellas Pharma Global Development | 89 | $152,746 |
| Sumitomo Pharma America, Inc. | 26 | $101,757 |
| Novartis | 28 | $95,552 |
| Jazz Pharmaceuticals Inc. | 75 | $57,037 |
| Bristol Myers Squibb | 28 | $15,141 |
| National Marrow Donor Program | 1 | $4,000 |
| Verastem, Inc. | 2 | $2,765 |
| AbbVie | 17 | $386 |
| Pharmacyclics LLC, An Abbvie Company | 10 | $312 |
| Johnson & Johnson | 7 | $240 |
| Pfizer | 4 | $181 |
| E.r. Squibb & Sons, L.L.C. | 2 | $170 |
| Astellas Pharma US Inc | 5 | $107 |
| Incyte Corporation | 5 | $90 |
| Genentech USA, Inc. | 4 | $81 |
| Blueprint Medicines Corporation | 3 | $72 |
| Amgen | 3 | $66 |
| Merck | 4 | $65 |
| Rigel Pharmaceuticals, Inc. | 1 | $63 |
| Daiichi Sankyo Inc. | 3 | $54 |
| Beigene USA, Inc. | 2 | $52 |
| Gilead | 1 | $49 |
| Genmab U.S., Inc. | 2 | $49 |
| GSK | 2 | $38 |
| Agios Pharmaceuticals, Inc. | 2 | $33 |
| Sanofi | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Seagen Inc. | 1 | $23 |
| Invivyd Inc | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Akcea Therapeutics, Inc. | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $15 |
| Adaptive Biotechnologies Corporation | 1 | $14 |
How this compares
$590,075 in reported general payments places this provider in the 70th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Denver
- Allen CohnDenver$13.5M
- Robert RifkinDenver$11.3M
- Henning SchadeDenver$9M
- Jeffrey MatousDenver$8.4M
- Peter ForsbergDenver$5.5M
- Tara GregoryDenver$3.5M
- Mabel MardonesDenver$3M
- Amy SchmidtDenver$2.8M
- Michael TeesDenver$2.7M
- Yousuf GaffarDenver$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.